Lotus Herbals didn't buy a beauty brand. It bought a service layer, and almost everyone is mispricing the difference.
KorinMi — Korean Skin Solutions — runs Korean skincare clinics. The concept is treatment first and product second. Reshbha Munjal and Jenovia Daun Jung built a model where the clinic does the diagnosis and the D2C line captures the repeat, and that ordering is the whole thing.
A pure beauty brand sells you a bottle and hopes you come back. A clinic-led model owns the relationship before the bottle exists. The product becomes the annuity sitting on top of a trust event the customer has already paid for.
This is why the Lotus Herbals check reads differently than a purely financial round. Lotus didn't just write from its innovation fund. It took a board seat. That brings distribution, regulatory muscle, sourcing and retail adjacency from a company that has spent decades learning Indian skin, Indian price points and Indian channel economics. For a clinic chain whose growth is a physical, city-by-city build, capital that de-risks the offline expansion is worth more than the ₹10 crore headline.
But this is still a small chain with a short operating history. Operational profitability within six months of one flagship Gurugram clinic, and 3,000-plus customers, is a promising signal and not a proven system. Clinic models break on the second, fifth and tenth location, where staffing, real estate and consistency quietly destroy unit economics.
The category thesis is attractive. The execution risk is high.
By mid-2027, if KorinMi has opened at least one more profitable clinic in a new city and clinic-attached product revenue is growing as a share of the mix, the service-layer thesis holds.
If it's still effectively one profitable clinic plus a D2C line, the moat was a story and they're just another beauty brand with a nicer waiting room.